MFSD12 as a Radioligand Therapy Target
MFSD12, major facilitator superfamily domain containing 12, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, MFSD12 staining is highest in thyroid cancer (100% of samples positive), testicular cancer (100% of samples positive) and glioma (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is MFSD12 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in thyroid cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
MFSD12 expression in cancer
Protein expression of MFSD12 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Thyroid Cancer | 0.83 | High | 100% |
| Testicular Cancer | 0.70 | High | 100% |
| Glioma | 0.67 | High | 100% |
| Melanoma | 0.61 | High | 92% |
| Colorectal Cancer | 0.61 | High | 83% |
| Breast Cancer | 0.61 | High | 91% |
| Neuroendocrine Tumors | 0.58 | High | 100% |
| Prostate Cancer | 0.47 | Medium | 80% |
| Bladder Cancer | 0.36 | Medium | 46% |
| Pancreatic Cancer | 0.36 | Medium | 58% |
| Head and Neck Cancer | 0.33 | Medium | 100% |
| Gastric Cancer | 0.27 | Medium | 40% |
| Skin Cancer | 0.24 | Medium | 55% |
| Liver Cancer | 0.22 | Medium | 58% |
| Cervical Cancer | 0.19 | Low | 42% |
| Lung Cancer | 0.19 | Low | 42% |
| Lymphoma | 0.19 | Low | 33% |
| Ovarian Cancer | 0.17 | Low | 33% |
| Endometrial Cancer | 0.12 | Low | 27% |
| Kidney Cancer | 0.11 | Low | 25% |
Is MFSD12 internalized?
Nuclens has not yet extracted internalization evidence for MFSD12. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
MFSD12 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for MFSD12 yet. Search ClinicalTrials.gov for MFSD12 trials.
MFSD12 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See MFSD12 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
MFSD12 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: 0.03 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related thyroid cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EPCAM · SSTR2 · EGFR · ITGAV · STEAP2 · FAP
See all radioligand therapy targets in thyroid cancer.
See how MFSD12 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.